Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21

Jacqueline D. Shields,^* Iraklis C. Kourtis,^* Alice A. Tomei, Joanna M. Roberts, Melody A. Swartz

Abstract: Tumor manipulation of host immunity is important for tumor survival and invasion. Many cancers secrete CCL21, a chemoattractant for various leukocytes and lymphoid tissue inducer cells, which drive lymphoid neogenesis. CCL21 expression by melanoma tumors in mice was associated with an immunotolerant microenvironment, which included the induction of lymphoid-like reticular stromal networks, an altered cytokine milieu, and the recruitment of regulatory leukocyte populations. In contrast, CCL21-deficient tumors induced antigen-specific immunity. CCL21-mediated immune tolerance was dependent on host rather than tumor expression of the CCL21 receptor, CCR7, and could protect distant, coimplanted CCL21-deficient tumors and even nonsyngeneic allografts from rejection. We suggest that by altering the tumor microenvironment, CCL21-secreting tumors shift the host immune response from immunogenic to tolerogenic, which facilitates tumor progression.

Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.

To whom all correspondence should be addressed. E-mail: melody.swartz{at}epfl.ch

Protective Role of the Inflammatory CCR2/CCL2 Chemokine Pathway through Recruitment of Type 1 Cytotoxic {gamma}{delta} T Lymphocytes to Tumor Beds.

T. Lanca, M. F. Costa, N. Goncalves-Sousa, M. Rei, A. R. Grosso, C. Penido, and B. Silva-Santos (2013)
J. Immunol. 190, 6673-6680
 |  Abstract »  |  Full Text »  |  PDF »

Trp53 Inactivation in the Tumor Microenvironment Promotes Tumor Progression by Expanding the Immunosuppressive Lymphoid-like Stromal Network.

G. Guo, L. Marrero, P. Rodriguez, L. Del Valle, A. Ochoa, and Y. Cui (2013)
Cancer Res. 73, 1668-1675
 |  Abstract »  |  Full Text »  |  PDF »

Engineering Approaches to Immunotherapy.

M. A. Swartz, S. Hirosue, and J. A. Hubbell (2012)
Science Translational Medicine 4, 148rv9
 |  Full Text »  |  PDF »

Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases.

A. Cipponi, M. Mercier, T. Seremet, J.-F. Baurain, I. Theate, J. van den Oord, M. Stas, T. Boon, P. G. Coulie, and N. van Baren (2012)
Cancer Res. 72, 3997-4007
 |  Abstract »  |  Full Text »  |  PDF »

Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy.

M. A. Swartz, N. Iida, E. W. Roberts, S. Sangaletti, M. H. Wong, F. E. Yull, L. M. Coussens, and Y. A. DeClerck (2012)
Cancer Res. 72, 2473-2480
 |  Abstract »  |  Full Text »  |  PDF »

Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes.

F. Guilloton, G. Caron, C. Menard, C. Pangault, P. Ame-Thomas, J. Dulong, J. De Vos, D. Rossille, C. Henry, T. Lamy, et al. (2012)
Blood 119, 2556-2567
 |  Abstract »  |  Full Text »  |  PDF »

Lymphangiogenesis and Cancer.

A. Christiansen and M. Detmar (2011)
Genes & Cancer 2, 1146-1158
 |  Abstract »  |  Full Text »  |  PDF »

CC chemokine ligand 21 enhances the immunogenicity of the breast cancer cell line MCF-7 upon assistance of TLR2.

S. Wu, X. Lu, Z. L. Zhang, P. Lei, P. Hu, M. Wang, B. Huang, W. Xing, X. T. Jiang, H. J. Liu, et al. (2011)
Carcinogenesis 32, 296-304
 |  Abstract »  |  Full Text »  |  PDF »

Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.

E. D. Thompson, H. L. Enriquez, Y.-X. Fu, and V. H. Engelhard (2010)
J. Exp. Med. 207, 1791-1804
 |  Abstract »  |  Full Text »  |  PDF »

Tumor Immune Evasion.

C. L. Zindl and D. D. Chaplin (2010)
Science 328, 697-698
 |  Abstract »  |  Full Text »  |  PDF »